Although RvD2 improved vascular dysfunction in AngII-treated mice, either in the absence [22] or presence [7] of dyslipidemia, no protective effect of GPR18 agonism through systemic RvD2 delivery was observed on the arterial stiffening of the small mesenteric arteries. The gene discussed is GPR18; the disease is metabolic syndrome.